2020 EACR Liquid Biopsies Sponsored Symposia NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics Erin Newburn, PhD Associate Director, Field Applications Scientist Dan Norton, MBA Sr. Product Manager NeXT Liquid Biopsy™, a first-of-its-kind, high-performance exome-wide [...]
2020 SITC: Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity T cells can inhibit tumor growth and progression by recognizing major histocompatibility complex class I (MHC-I) -bound peptides derived from antigens that are mutated, inappropriately expressed, or overexpressed in the tumor cells (vs. healthy cells). There are many mechanisms by which [...]
2020 SITC: B-cell receptor heavy chain repertoire profiling using an augmented transcriptome Comprehensively profiling the tumor and tumor microenvironment (TME) can help provide a more complete view of the complex interactions between the tumor and immune system, potentially furthering our understanding of tumor progression and response to treatment. We have developed an augmented, immuno-oncology-optimized exome/transcriptome [...]
2020 SITC: Profiling tumor circulating cell-free DNA with an enhanced whole-exome to enable sensitive assessment of somatic mutations The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically actionable [...]
2020 SITC: Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID NeXT™ Platform enables a [...]
2020 AMP: An exome and transcriptome based NeXT Dx™ test enables therapy selection for cancer patients and offers insight into emerging composite biomarkers for immunotherapy The emergence of immune checkpoint inhibitors has highlighted the potential of immuno-oncology therapeutics to produce unprecedented beneficial responses in cancer patients. However, diagnostic biomarkers that consistently predict patient response [...]
2020 EACR Liquid Biopsies: Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach The analysis of tumors using circulating cell-free DNA (cfDNA) is beginning to transform cancer diagnosis, prognosis, response to therapy and to enable disease progression monitoring. Most cfDNA assays are centered around the identification of therapeutically [...]
SHERPA™ Bioinformatics Engine Systematic HLA Epitope Ranking Pan Algorithm Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails the comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. The ImmunoID NeXT [...]
Powered by our ACE Technology, our DNA Assays provide more uniform coverage at high depths than standard assays. Specifically, our ACE-enabled assays outperform conventional exome assays by enhances coverage across coding regions and supplementing more complex areas in the genomic architecture such as GC-rich content. The Personalis solution provides targeted sequencing to augment coverage gaps [...]
Our patented ACE™ (Accuracy and Content Enhanced) Technology is the foundation of ImmunoID NeXT and all proprietary Personalis products. ACE improves processes from nucleic acid preparation, to sequencing, to analytics for superior sequencing results. Nucleic Acid Extraction and Sample Preparation Personalis has developed protocols to overcome the challenges of working with difficult samples including FFPE, [...]